Clinical Trial Update: PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating PCSK9 inhibition as secondary prevention in renal transplant recipients with high cardiovascular risk has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplant Recipients with High Cardiovascular Risk

Snippet

Sponsor: Hamid Al-Essa Organ Transplant Center | Conditions: Kideny Transplant Recipients With High Cardiovascular Risk Score | Phase 3 | Status: COMPLETED